RE: RE: RE: Snrkid saysAn interesting article on Why Big Pharma Mergers Magnify Failures. This provides a little more insight on what may be happening at the heart of the pharmaceutical industry and perhaps a little more vision regarding the Roche decision.
The article mentions that Products that are technically promising are terminated if the marketing potential is thought to be too small to make a difference to their total sales. Programs that are thought to have an annual sales potential of less that $1 billion are usually stopped in their tracks.
I think in our case there are certainly multiple factors in play, business direction decisions/market priorities, potential loss of revenue from traditional drugs, and/or reduced Biological product revenue, or down right unethical industry practices by some which has been pointed out.
https://business.theatlantic.com/2009/03/why_big_pharma_mergers_magnify_failures.php
I also found it fitting that a new Datamonitor report was advertised today...of particular interest was Chapter 6 items listed. No mention of Roche, the report was probably sponsered by them or they are planning a Roche only edition.
CHAPTER 6 PHARMACEUTICAL COMPANY 'ETHICS' 140
Clinical development 140
Clinical trial design to maximize perceived efficacy 140
Tekturna 140
Effient 141
Suppression of negative clinical data 141
Vytorin 142
Influencing the roster of the FDA Advisory Committee 142
Effient 143
Independent publication of safety concerns 143
Dr Steve Nissen and Avandia 143
Exerting pressure on critics 144
GlaxoSmithKline and Avandia 144
Influencing physicians 145
Commercial practices 145
Dose availability restriction 145
Pfizer and sildenafil 145
Anti-trust practices 146
Abbott 146
Co-development partnership 146
Pfizer and Nektar 146
Stakeholder Opinions: Commercial strategies in cardiovascular and metabolic diseases successful market positioning at company and brand level becomes paramount
https://www.reportlinker.com/p0116588/Stakeholder-Opinions-Commercial-strategies-in-cardiovascular-and-metabolic-diseases--successful-market-positioning-at-company-and-brand-level-becomes-paramount.html
Introduction
Datamonitor expects commercial strategies in the cardiovascular and metabolic markets to become increasingly important as the markets mature. The report details strategies used by pharmaceutical companies to capture market share, to differentiate brands from the competition, for revenue maximization and for the defense of brand revenues from generic competition.
Scope
-- Analysis of company and brand marketing positioning
-- Analysis of methods employed to bolster R&D pipelines
-- Analysis of the methods used to achieve brand differentiation and
revenue maximization